🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsOrforglipron Phase 2 weight loss data — 12 month update Page 4

Orforglipron Phase 2 weight loss data — 12 month update

JenPlateau Wed, Sep 11, 2024 at 8:13 PM 29 replies 2,118 viewsPage 4 of 6
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Sep 16, 2024 at 4:07 AM#16

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

Last edited: Sep 16, 2024 at 5:07 AM
28 1mona_PHX, andrew_nyc, Dr.EndoEP and 25 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Sep 16, 2024 at 7:02 AM#17
BiostatsBrad said:
If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.

29 2PharmHunterJen, TomTeleRx, DoseLogDan and 26 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Sep 16, 2024 at 9:57 AM#18
BiostatsBrad said:
If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

That reframing is the part I needed. Adding it to my notes with a link back to this thread.

Last edited: Sep 16, 2024 at 2:57 PM
30 3NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 27 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Sep 16, 2024 at 12:52 PM#19

Clinical perspective, offered as context rather than as advice. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: Sep 16, 2024 at 3:52 PM
31 4bbq_ray_KC, oliver_london, tane_welly and 28 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Sep 16, 2024 at 3:47 PM#20

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.

Last edited: Sep 16, 2024 at 7:47 PM
3 1PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph
Reply Quote Save Share Report

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register